AviadoBio

About:

AviadoBio transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies

Website: http://www.aviadobio.com

Twitter/X: AviadoBio

Top Investors: F-Prime Capital, New Enterprise Associates, LifeArc, Dementia Discovery Fund, EQT Life Sciences

Description:

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Total Funding Amount:

$114M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2019-01-01

Founders:

Jonathan Jones

Number of Employees:

11-50

Last Funding Date:

2024-10-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai